Characteristics and outcomes of patients (pts) with metastatic KRAS mutant lung adenocarcinomas: Lung Cancer Mutation Consortium (LCMC) database.
Badi El Osta(Emory University), Suresh S. Ramalingam(Emory University), Taofeek K. Owonikoko(UPMC Hillman Cancer Center), Gabriel Sica(Emory University), Lynne D. Berry(Vanderbilt University Medical Center), Mark G. Kris(Memorial Sloan Kettering Cancer Center), Bruce E. Johnson(Harvard University), Fadlo R. Khuri(American University of Beirut Medical Center), Paul A. Bunn(University of Colorado Denver), Sungjin Kim(Cedars-Sinai Medical Center), David J. Kwiatkowski(Brigham and Women's Hospital), Rathi N. Pillai(Emory University), Madhusmita Behera(National Institutes of Health)
Cited by 20
Related Papers
<i>EGFR</i> Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
|Science|2004|9.4k
<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
|Science|2007|4.5k
Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer
|New England Journal of Medicine|2016|3.3k
Genomic Classification of Cutaneous Melanoma
|Cell|2015|3.3k